Every two years, the World Health Organization publishes the Model List of Essential Medicines (EML), which consists of the basic medicines that should be available within all country’s health systems. Countries often base their national EMLs off this global standard, using it to inform which medicines are prioritized for budgeting, procurement, provider education, and patient treatment. Following a global effort led by the Diarrhea Innovations Group’a cross-sectoral coalition of innovators committed to reducing the global burden of enteric and diarrheal diseases [https://www.path.org/media-center/path-applauds-recognition-frontline-treatment-childhood-diarrheal-disease-world-health-organization/], the July 2019 WHO EML now includes co-packaged oral rehydration salts (ORS) and zinc sulfate for the treatment of diarrheal disease. This update signals the importance of co-packaged ORS and zinc for treatment of childhood diarrhea and is an opportunity to advocate for expanded access to this product worldwide [https://www.defeatdd.org/ors-zinc-copack].
Civil society partners can play a key role in ensuring the global EML reflects the health priorities of citizens, particularly the most vulnerable. Join PATH for a webinar to discuss advocacy strategies for ensuring the WHO EML is inclusive of lifesaving medicines for women’s, newborn’s, and children’s health, and supporting country uptake. Presenters will share learnings from recent successes elevating treatments for diarrheal disease, postpartum hemorrhage, and childhood pneumonia in global and national EMLs.
September 11, 2019
10:00-11:00 a.m. EST
RSVP HERE https://docs.google.com/forms/d/e/1FAIpQLScfihQ_7Ejxi4VpE1Di_0FA6Igsto6eiYn2t-HsV3cyjr91FQ/viewform
Join URL: https://zoom.us/j/307931177
Elena Pantjushenko, Communications and Advocacy Manager, PATH
Wanjiku Manguyu, Senior Advocacy and Policy Officer, PATH
Bonnie Keith, Senior Program and Policy Officer, PATH